United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
NCT Number: NCT01088386
The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Blue Bell, Pennsylvania, 19422, United States
The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS) by:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline to end of study
Time frame: Baseline to end of study
Time frame: Baseline to end of study
Eli Lilly and Company
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04987229
Bipolar I Disorder, Mental Disorders
Dothan, Alabama, United States
View Trial DetailsNCT06880796
Bipolar Disorder, Bipolar and Related Disorders
Providence, Rhode Island, United States
View Trial DetailsNCT07356765
Mental Disorders, Negative Symptoms of Schizophrenia
Tianjin, China
View Trial DetailsNCT05165316
Mental Disorders, Schizophrenia
Ramat Gan, Israel
View Trial Details